More research urged to compare and validate genomic tests in oncology

The European Society for Medical Oncology (ESMO) has welcomed preliminary clinical trial results that suggest genomic testing could allow many patients with early breast cancer to safely avoid chemotherapy. The new trial results, reported at the European Cancer Congress 2013 this week, illustrate that more research is urgently needed to compare and validate the growing number of genomic tests becoming available in oncology, ESMO says. Read more here.